Evidence map›Paper›PMID 37829270›Full record

ReviewPrzeglad menopauzalny = Menopause review2023

Rapidly growing uterine myoma - should we be afraid of it?

Marek Nowak, Wojciech Bartosik, Weronika Witana, Krzysztof Nowak, Julia Wilkusz

Open access · goldAbstract readReview
In one paragraph

Review in Przeglad menopauzalny = Menopause review, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Marek NowakDepartment of Operative Gynecology and Gynecologic Oncology of Polish Mother's Memorial Hospital - Research Institute, Łódź, Poland.
Wojciech BartosikDepartment of Operative Gynecology and Gynecologic Oncology of Polish Mother's Memorial Hospital - Research Institute, Łódź, Poland.
Weronika WitanaDepartment of Operative Gynecology and Gynecologic Oncology of Polish Mother's Memorial Hospital - Research Institute, Łódź, Poland.
Krzysztof NowakDepartment of Operative Gynecology and Gynecologic Oncology of Polish Mother's Memorial Hospital - Research Institute, Łódź, Poland.
Julia WilkuszStudents' Scientific Association, Medical University of Łódź, Łódź, Poland.
Medical University of Lodz · PLPolish Mother’s Memorial Hospital Research Institute · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During a year, myomas may undergo radical changes in their dimensions - from decreasing by 90% to growing by 200%. On average, myomas of the uterus increase in volume by 20-30% annually in the premenopausal period. On the other hand, myomas regress spontaneously in about 20% of women. After menopause uterine fibroids stabilize or regress. Every new or growing lesion of the uterus after menopause has to be diagnosed. There is no general definition of fast growing uterine myoma. The presence of fast growing uterine myoma, regardless of its definition, is associated with some clinical issues: it may become symptomatic (pain, bleeding, bulk symptoms), may be responsible for infertility, and a malignant process (leiomyosarcoma) may be present. Regardless of common belief, the risk of sarcoma is not related to the size of the uterus or its fast enlargement. The prevalence of sarcoma in myomas is 0.26%, and in rapidly growing myomas is 0.27%. Treatment should be individualized, selected for the age of the woman and her expectations (preservation of fertility, uterus), symptoms, size and localization of the myomas. The methods of surgical treatment of unsuspected "rapidly growing myomas" are the same as those of common uterine fibroids. Minimally invasive surgery is optimal, but a decision has to be made after evaluation of the risk factors of sarcoma.

Indexed as

fast enlargement of uterusfast growing myomasarcoma

Identifiers

PMID37829270
PMCPMC10566336
OpenAlexW4387195231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.